Skip to content

Study · Measured the body's own peptide · 2006

3 results

Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas.

Traub F, Jost M, Hess R, Schorn K, Menzel C, Budde P, Schulz-Knappe P, Lamping N, Pich A, Kreipe H, Tammen H

Laboratory investigation; a journal of technical methods and pathology1 Mar 2006Cited by 25 (Europe PMC)

PMID16485008 (opens in a new tab)DOI10.1038/labinvest.3700385 (opens in a new tab)PepBankPUB-16485008
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In breast cancer samples, the concentration of the body's own thymosin alpha‑1 was upregulated in estrogen-receptor-negative tumors.

    In plain wordsIn breast cancer samples, natural thymosin alpha‑1 levels were higher in estrogen-receptor-negative tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymosin alpha-1 concentration in estrogen-receptor-negative samples
    Study

    n = 37

    Invasive breast cancer tissue
    Comparator
    Estrogen-receptor-positive samples
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The concentration of Thymosin alpha-1 was found to be upregulated (n=37) in estrogen-negative cancer samples
    1 context sentence
    Summary · context
    The aim of this study was to investigate peptide profiles of invasive breast cancer with positive (n=39) and negative receptor status (n=41).

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In breast cancer samples, the concentration of the body's own thymosin alpha‑1 was downregulated in estrogen-receptor-positive tumors.

    In plain wordsIn breast cancer samples, natural thymosin alpha‑1 levels were lower in estrogen-receptor-positive tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseThymosin alpha-1 concentration in estrogen-receptor-positive samples
    Study

    n = 32

    Invasive breast cancer tissue
    Comparator
    Estrogen-receptor-negative samples
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    and downregulated (n=32) in estrogen-positive breast cancer samples.
    1 context sentence
    Summary · context
    The aim of this study was to investigate peptide profiles of invasive breast cancer with positive (n=39) and negative receptor status (n=41).

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In invasive breast cancer, the body's own thymosin alpha‑1 differentiated tumor samples by estrogen-receptor status with the highest specificity.

    In plain wordsIn breast cancer samples, natural thymosin alpha‑1 levels best separated receptor-positive from receptor-negative tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableDiscrimination of tumors by receptor status
    Study

    n: not reported in source

    Invasive breast cancer tissue
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    thymosin alpha-1, an asparaginyl endopeptidase generated cleavage product of the ubiquitous acidic protein prothymosin-alpha, was found to differentiate the tumor samples according to their receptor status with the highest specificity
    1 context sentence
    Summary · context
    The aim of this study was to investigate peptide profiles of invasive breast cancer with positive (n=39) and negative receptor status (n=41).

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.